Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4553 - Association between TP53 mutations and efficacy of Osimertinib for brain metastasis from EGFR-mutant lung cancer


28 Sep 2019


Poster Display session 1


Tumour Site

Central Nervous System Malignancies;  Thoracic Malignancies


Lijuan Chen


Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243


L. Chen1, X. Mu2, H. Wu2, Y. Zhao1

Author affiliations

  • 1 Oncology, The Affiliated Cancer Hospital of Zhengzhou University, 450008 - Zhengzhou/CN
  • 2 Oncology, Affiliated Cancer Hospital of Zhengzhou University, 450008 - Zhengzhou/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4553


Osimertinib was approved as a standard therapy for EGFR-mutant lung cancer with brain metastasis. It has been demonstrated that TP53 mutations was responsible for Gefitinib resistance in a preclinical study. This study was to analyze the impact of TP53 mutations on response to first-line Osimertinib in EGFR-mutant patients with brain metastasis from non-small cell lung cancer (NSCLC).


100 EGFR-mutated NSCLC patients with brain metastasis receiving first-line Osimertinib were analyzed. TP53 mutations were evaluated in all patients in relation to disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).


TP53 mutations were observed in 48 (48%), 11 (22.92%), 7 (14.58%), 12 (25%) and 18 (37.5%) patients in exon 5, 6, 7, and 8, respectively. TP53 mutations were significantly associated with increasing brain-metastatic sites (P < 0.05). DCR was 29.17% in TP53-mutated patients compared to 94.23% in patients with TP53-wild type (P < 0.05). All patients with TP53 exon 8 mutations had primary resistance to Osimertinib. Compared with others, significantly shorter median PFS and OS were observed both in total TP53-mutated patients (mPFS 4.8 vs 10 months, P < 0.001; mOS 10.98 vs 25.45 months, P < 0.001) and patients with TP53 exon 8 mutations ((mPFS 4 vs 9 months, P < 0.001; mOS 8.25 vs 19.98 months, P < 0.001)), compared with others. TP53 exon 8 mutation was an independent prognostic factor adjusting for other subtypes of TP53 mutation (P < 0.001).


TP53 mutations, especially exon 8 mutations, reduced the efficacy of Osimertinib and worsen prognosis in EGFR-mutated NSCLC patients with brain metastasis. TP53 mutation might be used as a predictor for Osimertinib therapy and a prognostic factor for EGFR-mutated NSCLC patients with brain metastasis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Yanqiu Zhao.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.